How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.

Özkan AlanOkan KuzhanSinan KocaTuğba Akın TelliTugba BasogluOzlem ErcelepDeniz FilinteYildiz SengulHuseyin ArikanSerap KayaNalan Akgul BabacanFaysal DanePerran Fulden Yumuk

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)

A molecular-targeted drug (anaplastic lymphoma kinase inhibitor) was found to be extremely effective as selective therapy for inflammatory myofibroblastic tumor with anaplastic lymphoma kinase translocation. Here, we want to emphasize the continuation of this treatment after achieving a good response until progression or a major side effect.

Keyphrases

advanced non small cell lung cancer
diffuse large b cell lymphoma
oxidative stress
cancer therapy
emergency department
tyrosine kinase
adverse drug
drug induced
replacement therapy
electronic health record